Sunflower Pharmaceutical Group Co.,Ltd

Shenzhen Stock Exchange 002737.SZ

Sunflower Pharmaceutical Group Co.,Ltd Capital Expenditure for the year ending December 31, 2023: USD -21.01 M

Sunflower Pharmaceutical Group Co.,Ltd Capital Expenditure is USD -21.01 M for the year ending December 31, 2023, a 5.18% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Sunflower Pharmaceutical Group Co.,Ltd Capital Expenditure for the year ending December 31, 2022 was USD -22.16 M, a -18.99% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd Capital Expenditure for the year ending December 31, 2021 was USD -18.62 M, a 42.87% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd Capital Expenditure for the year ending December 31, 2020 was USD -32.59 M, a 39.36% change year over year.
Sunflower Pharmaceutical Group Co.,Ltd Capital Expenditure for the year ending December 31, 2019 was USD -53.74 M, a -15.19% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Shenzhen Stock Exchange: 002737.SZ

Sunflower Pharmaceutical Group Co.,Ltd

CEO	Ms. Yi Guan
IPO Date	Dec. 30, 2014
Location	China
Headquarters	Concentrated Area, Yingbin Road
Employees	5,776
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sunflower Pharmaceutical Group Co.,Ltd researches, develops, manufactures, and markets Chinese patent medicines in China. The company also produces chemical, biological, and health care medicines. Its products are used in therapeutic areas, such as pediatrics, gynecology, digestive system, respiratory and cold, rheumatism and bone disease, and cardiovascular and cerebrovascular. The company sells its products under the Sunflower and Little Sunflower brands. Sunflower Pharmaceutical Group Co.,Ltd was founded in 2005 and is based in Harbin, China.

Key trends

Past 5 years